MedTrace Logo

Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children

NCT05613062 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-07-07

No results posted yet for this study

Summary

The study aims to evaluate the clinical efficacy of Chinese medicine (CM) for the treatment of subacute and chronic Atopic Dermatitis (AD) patients when compared to the placebo control by examining the clinical symptoms.

Conditions

Interventions

DRUG

Modified Huang-Lian-Jie-Du Decoction (MHLJDD)

Chinese medicine granules for 12 weeks twice daily

DRUG

Placebo

Placebo granules for 12 weeks twice daily

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Zhixiu Lin · Integrative Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-11
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05613062 on ClinicalTrials.gov